{"id":"hl301-experimental","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Rash"},{"rate":"null","effect":"Pneumonitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the PD-1/PD-L1 interaction, HL301 aims to restore the body's natural ability to recognize and attack cancer cells. This mechanism is thought to be effective in various types of cancer, including non-small cell lung cancer and melanoma.","oneSentence":"HL301 is an experimental drug that targets the PD-1/PD-L1 pathway to enhance anti-tumor immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:48.008Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Melanoma"}]},"trialDetails":[{"nctId":"NCT06434792","phase":"PHASE2","title":"Study to Evaluate Efficacy and Safety of Bronpass Tab. in Patients With Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2023-06-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":96},{"nctId":"NCT04632342","phase":"PHASE2","title":"Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of HL301 on Radiation Pneumonitis in Non-small Cell Lung Cancer Patients","status":"UNKNOWN","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2020-11","conditions":"Radiation Pneumonitis, Lung Cancer","enrollment":87},{"nctId":"NCT03654196","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Umkamin Tab in Acute Bronchitis Patients","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2018-03-16","conditions":"Acute Bronchitis","enrollment":246},{"nctId":"NCT03309800","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Placebo in Acute Bronchitis Patients","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2017-03-29","conditions":"Acute Bronchitis","enrollment":168},{"nctId":"NCT02250027","phase":"PHASE2","title":"A Multicenter, Randomized, Double-blind, Parallel Group Study to Determine the Optimal Dose of HL301 After 7 Days Oral Administration in Acute Bronchitis or Acute Exacerbations of Chronic Bronchitis Patients (HL301: Mixed Extract of Rehmannia Glutinosa, Schisandra and so on)","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2014-03","conditions":"Acute Bronchitis, Acute Exacerbations of Chronic Bronchitis","enrollment":156}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HL301 and Placebo of Umkamin"],"phase":"phase_3","status":"active","brandName":"HL301(Experimental)","genericName":"HL301(Experimental)","companyName":"Hanlim Pharm. Co., Ltd.","companyId":"hanlim-pharm-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HL301 is an experimental drug that targets the PD-1/PD-L1 pathway to enhance anti-tumor immune response. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}